indian patent for cox-2 inhibitor

The Company advises that its wholly-owned subsidiary, Cambridge Scientific Pty Ltd (CSPL) has today received
the Letters Patent for Indian Patent No. PCT/AU2007/000555 entitled Cox-2 Inhibitor Isolated from Plasma.

The terms of the Letters Patent is for 20 years commencing from 27 April 2007 and expiring 27 April 2027.

This patent describes the process of producing a selective inhibitor, a form of non-steroidal anti-inflammatory drug,
directly targeting COX-2, an enzyme responsible for inflammation.

The Company expects that successful patent allowances will be repeated in other jurisdictions where corresponding
applications are in advanced stages of examination.

Cambridge Scientific now holds granted patents for the Cox2 Inhibitor in Australia, USA, India, South Africa and
New Zealand.